News

Long noncoding RNA may be new biomarker for PAH: Study

A long noncoding RNA molecule (lncRNA) — a long segment of RNA that regulates protein production in the body — may activate or inhibit genes associated with pulmonary arterial hypertension (PAH), according to researchers in China. In their study, a lncRNA was found at higher levels in children with…

Genes may be targets to treat right heart failure linked to PAH

Certain genes are differentially expressed, meaning they have different activity, in people with pulmonary arterial hypertension (PAH) whose right side of the heart fails to work as it should, a study found. Researchers believe that those genes, generally involved in regulating the electrical properties of the heart’s muscle cells,…

Left heart dysfunction poses great risk for CTEPH patients: Large study

Researchers have identified a significant risk factor that affects the prognosis of people with chronic thromboembolic pulmonary hypertension (CTEPH) in a large 26-year study. They found that elevated left ventricular filling pressure (LVFP), a measure of left heart function, was common in patients and predicted worse outcomes. Pulmonary hypertension…

Macitentan and tadalafil combo may be better than either drug alone

An investigational once-daily therapy, a single tablet combining macitentan and tadalafil, significantly improved pulmonary blood flow compared with macitentan or tadalafil alone in pulmonary arterial hypertension (PAH) patients taking part in the Phase 3 A DUE study. Because these medications target different PAH-related pathways, current guidelines recommend initially treating…

A Conversation With Rare Disease Advocates